Global Population Sequencing Market: Focus on Product, Method, Technology, Application, Country, and Competitive Landscape - Analysis and Forecast, 2020-2030

September 2020 | 200 pages | ID: G044E3C85DCBEN
BIS Research Inc.

Abstracts

Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.

Market Report Coverage - Global Population Sequencing Market

Market Segmentation

• Product Type – Kits and Assays, Platforms, Software Tools
• Application- Human Health, Molecular Forensics, Blockchain in Genomics
• Methods- Whole Genome Sequencing, Whole Exome Sequencing, Single-Read Sequencing, and Other Sequencing Methods
• Technology- Next-Generation Sequencing, Polymerase Chain Reaction and Other Technologies

Growth Drivers

• Rising Adoption of Large-Scale Sequencing to Understand the Genomics of Susceptibility and Resistance from COVID-19
• Increasing Adoption of Personalized Medicine for the Screening and Diagnostics of Genetic Disorders
• Global Surge in Direct-to-Consumer (DTC) Genetic Testing

Market Challenges

• Lack of Infrastructure to Maintain, Store and Share Sensitive Genomic Data
• Absence of Sufficient Funding for Development of High-Throughput Genomic Software Tools
• Poor Reducibility and Translatability of Data in Clinical Practice

Market Opportunities

• Advancing Precision Medicine with Blockchain-Powered Artificial Intelligence
• Technological Advancements in Sample Preparation for Population Sequencing
• Increased Population Engagement and Data Management

Key Companies Profiled

Thermo Fisher Scientific, Illumina Inc., Pacific Biosciences of California, Inc., Qiagen N.V., Oxford Nanopore Technologies, Inc., and Agilent Technologies, Inc., Genuity Science, F. Hoffman La-Roche Ltd., Nebula Genomics, Inc., Helix Opco, LLC, Beijing Genomics Institute, and Agilent Technologies, Inc.

Key Questions Answered in this Report:

• What are the major market drivers, challenges, and opportunities in the global population sequencing market?
• What is the potential impact of sequencing and biotechnological advancement in the application of genomic medicine and translational research?
• What is the current market expense along with future expected expenses in population sequencing initiatives?
• How population sequencing helped genomic tests to become a prominent tool for diagnostics in various clinical applications?
• What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
• How is each segment of the market expected to grow during the forecast period from 2020 to 2030 based on:
• product type
• method
• application
• technology
• country
• Who are the leading players with significant offerings to the global population sequencing market? What is the expected market dominance for each of these leading players?
• Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the population sequencing industry?

Market Overview

As per BIS Research analysis, the population sequencing market is projected to reach $64,047.6 million by 2030 from $21,730.4 million in 2020, at a CAGR of 11.41% during the forecast period, 2020-2030. Growth in this market is expected to be driven by the rising adoption of large-scale sequencing to understand the genomics of susceptibility and resistance from COVID-19, increasing adoption of personalized medicine for the screening and diagnosis of genetic disorders, and a global surge in direct-to-consumer genetic testing. However, there are significant challenges that are restraining the market growth, such as lack of infrastructure to maintain, store, and share sensitive genomic data, absence of sufficient funding for the development of high-throughput genomic software tools, and poor reducibility and transability of data in clinical practice.

The market is favored by the technological advancements in the sequencing, and computational analysis solutions for large volume of genetic data enabling deep understanding of the genetic variants for the development of diagnostics, drug discovery, and translational research.

Furthermore, several sequencing companies are focusing on the development of high-throughput sequence platforms and polymerase chain reaction platforms, with higher sensitivity and low turn-around time to benefit the patients, enabling patient-based outcomes and implementing genomic medicine.

Within the research report, the market is segmented on the basis of product type, application, methods, and technology. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of rapid diagnostics providing information on genetic mutation and optimal candidates for adjuvant chemotherapy or hormonal therapy. Due to the diverse product portfolio and intense market penetration, Illumina, Inc. has been a pioneer in this field and has been a significant competitor in this market.

The population sequencing market provided immense growth opportunities for the companies providing technology and infrastructure for large-scale health initiatives, such as Color Genomics, Inc., Helix Opco, LLC, and big data companies such as Genuity Science

Contents

Executive Summary

1 PRODUCT DEFINITION

1.1 Definition by Product
  1.1.1 Platforms
  1.1.2 Kits and Assays
  1.1.3 Software Tools
1.2 Inclusion and Exclusion
  1.2.1 Inclusion and Exclusion for Country-Wise Market Estimation
1.3 Scope of Work
1.4 Key Questions Answered in the Report

2 RESEARCH METHODOLOGY

2.1 Primary Data Sources
2.2 Secondary Data Sources
2.3 Market Estimation Model
2.4 Criteria for Company Profiling

3 INTRODUCTION

3.1 Market Overview
3.2 Impact of COVID-19 on Population Sequencing
3.3 Future Potential

4 GLOBAL POPULATION SEQUENCING MARKET DYNAMICS

4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
  4.3.1 Rising Adoption of Large-Scale Sequencing to Understand the Genomics of Susceptibility and Resistance from COVID-19
  4.3.2 Increasing Adoption of Personalized Medicine for the Screening and Diagnostics of Genetic Disorders
  4.3.3 Global Surge in Direct-to-Consumer (DTC) Genetic Testing
4.4 Market Restraints
  4.4.1 Lack of Infrastructure to Maintain, Store and Share Sensitive Genomic Data
  4.4.2 Absence of Sufficient Funding for Development of High-Throughput Genomic Software Tools
  4.4.3 Poor Reducibility and Translatability of Data in Clinical Practice
4.5 Market Opportunity
  4.5.1 Advancing Precision Medicine with Blockchain-Powered Artificial Intelligence
  4.5.2 Technological Advancements in Sample Preparation for Population Sequencing
  4.5.3 Increased Population Engagement and Data Management

5 COMPETITIVE LANDSCAPE

5.1 Key Strategies and Developments
  5.1.1 Product Approval
  5.1.2 Product Launches and Upgradations
  5.1.3 Synergistic Activities
  5.1.4 Funding and Expansion
  5.1.5 Acquisitions
  5.1.6 Other

6 INDUSTRY INSIGHTS

6.1 Overview
6.2 Legal Requirements and Framework in the U.S.
6.3 Legal Requirements and Framework in Europe
6.4 Legal Requirements and Framework in Asia-Pacific
  6.4.1 Japan
6.5 Market Share Analysis (by Company) 2019
  6.5.1 Growth Share Analysis (Opportunity Mapping)
  6.5.2 By Company

7 GLOBAL POPULATION SEQUENCING INITIATIVES (BY COUNTRY)

7.1 U.S.
7.2 Canada
  7.2.1 Population Sequencing Program
7.3 The U.K.
  7.3.1 Industrial Partnership Directing the Course of Genomic Medicine
7.4 Estonia
7.5 Germany
7.6 France
7.7 Ireland
7.8 Netherlands
7.9 Denmark
7.1 Japan
7.11 China
7.12 Australia
7.13 Saudi Arabia
7.14 Qatar
7.15 Turkey
7.16 Dubai

8 GLOBAL POPULATION SEQUENCING MARKET (BY PRODUCT), $MILLION, 2019-2030

8.1 Introduction
8.2 Kits and Assays
8.3 Platforms
8.4 Software Tools

9 GLOBAL POPULATION SEQUENCING MARKET (BY METHODS), $MILLION, 2019-2030

9.1 Introduction
9.2 Whole Genome Sequencing
9.3 Whole Exome Sequencing
9.4 Single-Read Sequencing
9.5 Other Sequencing Methods

10 GLOBAL POPULATION SEQUENCING MARKET (BY TECHNOLOGY), $MILLION, 2019-2030

10.1 Introduction
10.2 Polymerase Chain Reaction (PCR)
10.3 Next Generation Sequencing (NGS)
10.4 Other Technologies

11 GLOBAL POPULATION SEQUENCING MARKET (BY APPLICATION), $MILLION, 2019-2030

11.1 Introduction
11.2 Human health
  11.2.1 Clinical Applications
    11.2.1.1 Diagnostics
      11.2.1.1.1 Cancer Diagnostics
      11.2.1.1.2 Infectious Disease Diagnostics
      11.2.1.1.3 Rare Disease Diagnostics
      11.2.1.1.4 Other Diagnostics
    11.2.1.2 Drug Discovery and Development
  11.2.2 Translational Research Sequencing
11.3 Molecular Forensics
11.4 Blockchain in Genomics
  11.4.1 Data Sharing and Monetization
  11.4.2 Data Storage and Security
  11.4.3 Automated Health Insurance

12 GLOBAL POPULATION SEQUENCING MARKET (BY COUNTRY), $MILLION, 2019-2030

12.1 U.S. Population Sequencing Market, $Million, 2019-2030
12.2 Canada Population Sequencing Market, $Million, 2019-2030
12.3 U.K. Population Sequencing Market, $Million, 2019-2030
12.4 Germany Population Sequencing Market, $Million, 2019-2030
12.5 Denmark Population Sequencing Market, $Million, 2019-2030
12.6 Ireland Population Sequencing Market, $Million, 2019-2030
12.7 Estonia Population Sequencing Market, $Million, 2019-2030
12.8 Finland Population Sequencing Market, $Million, 2019-2030
12.9 Netherlands Population Sequencing Market, $Million, 2019-2030
12.1 China Population Sequencing Market, $Million, 2019-2030
12.11 Japan Population Sequencing Market, $Million, 2019-2030
12.12 Saudi Arabia Population Sequencing Market, $Million, 2019-2030
12.13 Turkey Population Sequencing Market, $Million, 2019-2030
12.14 Qatar Population Sequencing Market, $Million, 2019-2030

13 COMPANY PROFILES

13.1 Agilent Technologies, Inc.
  13.1.1 Company Overview
  13.1.2 Role of Agilent Technologies, Inc. in Global Population Sequencing Market
  13.1.3 Financials
  13.1.4 Key Insights About Financial Health of the Company
  13.1.5 SWOT Analysis
13.2 Beijing Genomics Institute (BGI)
  13.2.1 Company Overview
  13.2.2 Role of BGI in Global Population Sequencing Market
  13.2.3 SWOT Analysis
13.3 Color Genomics, Inc.
  13.3.1 Company Overview
  13.3.2 Role of Color Genomics, Inc. in Global Population Sequencing Market
  13.3.3 SWOT Analysis
13.4 F. Hoffmann-La Roche Ltd
  13.4.1 Company Overview
  13.4.2 Role of F. Hoffmann-La Roche Ltd in Global Population Sequencing Market
  13.4.3 Financials
  13.4.4 Key Insights About Financial Health of the Company
  13.4.5 SWOT Analysis
13.5 Genuity Science
  13.5.1 Company Overview
  13.5.2 Role of Genuity Science in Global Population Sequencing Market
  13.5.3 SWOT Analysis
13.6 Helix OpCo, LLC
  13.6.1 Company Overview
  13.6.2 Role of Helix Opco, LLC in Global Population Sequencing Market
  13.6.3 SWOT Analysis
13.7 Illumina, Inc.
  13.7.1 Company Overview
  13.7.2 Role of Illumina, Inc. in Global Population Sequencing Market
  13.7.3 Financials
  13.7.4 Key Insights About Financial Health of the Company
  13.7.5 SWOT Analysis
13.8 Nebula Genomics, Inc.
  13.8.1 Company Overview
  13.8.2 Role of Nebula Genomics, Inc. in Global Population Sequencing Market
  13.8.3 SWOT Analysis
13.9 Oxford Nanopore Technologies, Inc.
  13.9.1 Company Overview
  13.9.2 Role of Oxford Nanopore Technologies, Inc. in Global Population Sequencing Market
  13.9.3 SWOT Analysis
13.1 Pacific Biosciences of California, Inc.
  13.10.1 Company Overview
  13.10.2 Role of Pacific Biosciences of California, Inc. in Global Population Sequencing Market
  13.10.3 Financials
  13.10.4 Key Insights About Financial Health of the Company
  13.10.5 SWOT Analysis
13.11 QIAGEN N.V.
  13.11.1 Company Overview
  13.11.2 Role of QIAGEN N.V. in Global Population Sequencing Market
  13.11.3 Financials
  13.11.4 Key Insights About Financial Health of the Company
  13.11.5 SWOT Analysis
13.12 Thermo Fisher Scientific Inc.
  13.12.1 Company Overview
  13.12.2 Role of Thermo Fisher Scientific Inc. in Global Population Sequencing Market
  13.12.3 Financials
  13.12.4 Key Insights About Financial Health of the Company
  13.12.5 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 4.1: Likert Scale
Table 4.2: Impact Analysis of Market Drivers
Table 4.3: Impact Analysis of Market Restraints
Table 4.4: Per Sample Clinical Cost of WGS and WES
Table 7.1: Population Sequencing Initiative in U.S.
Table 7.2: Funding Allocated to Different Agencies
Table 7.3: Population Sequencing Initiative in Canada
Table 7.4: National and International Initiatives in Canada
Table 7.5: Ongoing Population Sequencing Program
Table 7.6: Population Sequencing Initiatives in the U.K.
Table 7.7: Key Investments Driving Genomic Medicine in the U.K.
Table 7.8: Genomic Medicine Centers in the U.K.
Table 7.9: Population Genomic Initiatives in Estonia
Table 7.10: Population Genomic Initiatives in Germany
Table 7.11: Population Genomic Initiatives in France
Table 7.12: French Genomic Platform
Table 7.13: Population Genomic Initiatives in Ireland
Table 7.14: Population Genomic Initiatives in Netherlands
Table 7.15: Population Genomic Initiatives in Denmark
Table 7.16: Population Sequencing Initiative in Japan
Table 7.17: Population Sequencing Initiative in China
Table 7.18: Population Sequencing Initiative in Australia
Table 7.19: Population Sequencing Initiative in Saudi Arabia
Table 7.20: Genome Sequencing Centers
Table 7.21: Population Sequencing Initiative in Qatar
Table 7.22: Population Sequencing Initiative in Turkey
Table 7.23: Population Sequencing Initiative in Dubai
Table 8.1: Market Available Sequencing Kits and Assays
Table 8.2: Market Available Population Sequencing Platforms
Table 8.3: Market Available Population Sequencing Software Tools

List Of Figures

LIST OF FIGURES

Figure 1: Total Global Disease Burden (by Cause), 2010- 2017
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Population Sequencing Market
Figure 3: Global Population Sequencing Market (by Product Type), $Million, 2020 vs. 2030
Figure 4: Global Population Sequencing Market (by Application), $Million, 2020 vs. 2030
Figure 5: Global Population Sequencing Market (by Method), $Million, 2020 vs. 2030
Figure 6: Global Population Sequencing Market (by Technology), $Million, 2020 vs. 2030
Figure 7: Global Population Sequencing Market Snapshot
Figure 1.1: Global Population Sequencing Market Segments Primary Research Methodology
Figure 2.1: Bottom-Up Approach (Segment-Wise Analysis)
Figure 2.2: Top-Down Approach (Segment-Wise Analysis)
Figure 3.1: Evolution of Population Sequencing
Figure 3.2: Active Population Sequencing Initiatives
Figure 4.1: U.S. Prevalence of Lyme Disease 2009-2018:
Figure 4.2: Global Prevalence Rate of Selected Rare Diseases Per 100,000 People
Figure 4.3: Number of People Tested by Consumer Genetics Companies (as of 2019)
Figure 5.1: Share of Key Developments and Strategies, 2017–2020
Figure 5.2: Product Approval Share (by Company), 2017–2020
Figure 5.3: Product Launch and Upgradation Share (by Company), 2017–2020
Figure 5.4: Synergistic Activities Share (by Company), 2017-2020
Figure 5.5: Funding and Expansion Share (by Company), 2017-2020
Figure 5.6: Acquisitions Share (by Company), 2017-2020
Figure 5.7: Other Key Development Share (by Company), 2017-2020
Figure 6.1: Regulatory Scenario in Europe (by Country)
Figure 6.2: Assessment of Commercialization Strategy in Japan
Figure 6.3: Market Share Analysis for the Global Population Sequencing Market 2019
Figure 6.4: Growth Share Matrix for Global Population Sequencing Market (by Company), 2019
Figure 7.1: Genome Centers in Canada
Figure 7.2: Member of the GENE Consortium
Figure 8.1: Global Population Sequencing Market (by Product), $Million, 2019-2030
Figure 8.2: Global Population Sequencing Market (Kits and Assays), $Million, 2019-2030
Figure 8.3: Global Population Sequencing Market (by Platforms), $Million, 2019-2030
Figure 8.4: Global Population Sequencing Market (by Software tools), $Million, 2019-2030
Figure 9.1: Global Population Sequencing Market (by Methods), $Million, 2019-2030
Figure 9.2: Global Population Sequencing Market (Whole Genome Sequencing), $Million, 2019-2030
Figure 9.3: Global Population Sequencing Market (Whole Exome Sequencing), $Million, 2019-2030
Figure 9.4: Global Population Sequencing Market (Single-Read Sequencing), $Million, 2019-2030
Figure 9.5: Global Population Sequencing Market (Other Sequencing Methods), $Million, 2019-2030
Figure 10.1: Global Population Sequencing Market (by Technology), $Million, 2019-2030
Figure 10.2: Global Population Sequencing Market (PCR), $Million, 2019-2030
Figure 10.3: Global Population Sequencing Market (NGS), $Million, 2019-2030
Figure 10.4: Global Population Sequencing Market (Other Technologies), $Million, 2019-2030
Figure 11.1: Global Population Sequencing Market (by Application), $Million, 2019-2030
Figure 11.2: Global Population Sequencing Market (Human Health), $Million, 2019-2030
Figure 11.3: Global Population Sequencing Market (by Human Heath Application), $Million, 2019-2030
Figure 11.4: Global Population Sequencing Market (by Clinical Application), $Million, 2019-2030
Figure 11.5: Global Population Sequencing Market (by Clinical Application), $Million, 2019-2030
Figure 11.6: Global Population Sequencing Market (Diagnostics Application) ($Million), 2019-2030
Figure 11.7: Global Population Sequencing Market (Diagnostics Application) ($Million), 2019-2030
Figure 11.8: Global Population Sequencing Market (Cancer Diagnostics), $Million, 2019-2030
Figure 11.9: Global Population Sequencing Market (Infectious Disease Diagnostics), $Million, 2019-2030
Figure 11.10: Global Population Sequencing Market (Rare Disease Diagnostics), $Million, 2019-2030
Figure 11.11: Global Population Sequencing Market (Other Diagnostics), $Million, 2019-2030
Figure 11.12: Global Population Sequencing Market (Diagnostics Application), $Million, 2019-2030
Figure 11.13: Global Population Sequencing Market (Translational Research), $Million, 2019-2030
Figure 11.14: Global Population Sequencing Market (Molecular Forensics), $Million, 2019-2030
Figure 11.15: Global Population Sequencing Market (Blockchain in Genomics), $Million, 2019-2030
Figure 11.16: Global Population Sequencing Market (Blockchain in Genomics), $Million, 2019-2030
Figure 11.17: Global Population Sequencing Market (Data Sharing and Monetization), $Million, 2019-2030
Figure 11.18: Global Population Sequencing Market (Data Storage and Security), $ Millions, 2019-2030
Figure 11.19: Global Population Sequencing Market (Automated Health Insurance), $Millions, 2019-2030
Figure 12.1: Global Population Sequencing Market (by Country), $Million, 2020 and 2030
Figure 12.2: U.S. Population Sequencing Market $Million, 2019-2030
Figure 12.3: Canada Population Sequencing Market $Million, 2019-2030
Figure 12.4: U.K. Population Sequencing Market $Million, 2019-2030
Figure 12.5: Germany Population Sequencing Market $Million, 2019-2030
Figure 12.6: Denmark Population Sequencing Market $Million, 2019-2030
Figure 12.7: Ireland Population Sequencing Market $Million, 2019-2030
Figure 12.8: Estonia Population Sequencing Market $Million, 2019-2030
Figure 12.9: Finland Population Sequencing Market $Million, 2019-2030
Figure 12.10: Netherlands Population Sequencing Market $Million, 2019-2030
Figure 12.11: China Population Sequencing Market $Million, 2019-2030
Figure 12.12: Japan Population Sequencing Market $Million, 2019-2030
Figure 12.13: Saudi Arabia Population Sequencing Market $Million, 2019-2030
Figure 12.14: Saudi Arabia Population Sequencing Market $Million, 2019-2030
Figure 12.15: Qatar Population Sequencing Market $Million, 2019-2030
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Agilent Technologies, Inc.: Product Portfolio
Figure 13.3: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 13.4: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 13.5: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 13.6: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 13.7: Agilent Technologies, Inc.: SWOT Analysis
Figure 13.8: BGI:Product Portfolio
Figure 13.9: BGI: SWOT Analysis
Figure 13.10: Color Genomic, Inc.: Product Portfolio
Figure 13.11: Color Genomics, Inc.: SWOT Analysis
Figure 13.12: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 13.13: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 13.14: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 13.15: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 13.16: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 13.17: Genuity Science.: Overall Product Portfolio
Figure 13.18: Genuity Science: SWOT Analysis
Figure 13.19: Helix Opco LLC: Product Portfolio
Figure 13.20: Helix Opco, LLC: SWOT Analysis
Figure 13.21: Illumina, Inc.: Overall Product Portfolio
Figure 13.22: Illumina, Inc.: Overall Financials, 2017-2019
Figure 13.23: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 13.24: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 13.25: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 13.26: Illumina, Inc.: SWOT Analysis
Figure 13.27: Nebula Genomics, Inc.: Overall Product Portfolio
Figure 13.28: Nebula Genomics, Inc.: SWOT Analysis
Figure 13.29: Oxford Nanopore Technologies, Inc.: Product Offerings
Figure 13.30: Oxford Nanopore Technologies, Inc.: SWOT Analysis
Figure 13.31: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 13.32: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
Figure 13.33: Pacific Biosciences of California, Inc.: Revenue (By Segment), 2017-2019
Figure 13.34: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
Figure 13.35: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
Figure 13.36: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 13.37: QIAGEN N.V.: Product Portfolio
Figure 13.38: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 13.39: QIAGEN N.V.: Revenue (by Product Segment), 2017-2019
Figure 13.40: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 13.41: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 13.42: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 13.43: QIAGEN N.V.: SWOT Analysis
Figure 13.44: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 13.45: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 13.46: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
Figure 13.47: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 13.48: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 13.49: Thermo Fisher Scientific Inc.: SWOT Analysis